Staquis

RSS

crisaborole

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Staquis has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 08/02/2022

Authorisation details

Product details
Name
Staquis
Agency product number
EMEA/H/C/004863
Active substance
Crisaborole
International non-proprietary name (INN) or common name
crisaborole
Therapeutic area (MeSH)
Dermatitis, Atopic
Anatomical therapeutic chemical (ATC) code
D11AH06
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG 
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
27/03/2020
Contact address

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

01/10/2021 Staquis - EMEA/H/C/004863 - N/0006

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other dermatological preparations

Therapeutic indication

Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ≤ 40% body surface area (BSA) affected.

Assessment history

How useful was this page?

Add your rating